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In order for synthetic polymers to ﬁnd widespread practical application as biomaterials, their syntheses
must be easy to perform, utilising freely available building blocks, and should generate products which
have no adverse eﬀects on cells or tissue. In addition, it is highly desirable that the synthesis platform for
the biomaterials can be adapted to generate polymers with a range of physical properties and macromol-
ecular architectures, and with multiple functional handles to allow derivatisation with ‘actives’ for sensing
or therapy. Here we describe the syntheses of amphiphilic tri- and tetra-block copolymers, using diazabi-
cyclo[5.4.0]undec-5-ene (DBU) as a metal-free catalyst for ring-opening polymerisations of the widely-
utilised monomer lactide combined with a functionalised protected cyclic carbonate. These syntheses
employed PEGylated macroinitiators with varying chain lengths and architectures, as well as a labile-ester
methacrylate initiator, and produced block copolymers with good control over monomer incorporation,
molar masses, side-chain and terminal functionality and physico-chemical properties. Regardless of the
nature of the initiators, the ﬁdelity of the hydroxyl end group was maintained as conﬁrmed by a second
ROP chain extension step, and polymers with acryloyl/methacryloyl termini were able to undergo a
second tandem reaction step, in particular thiol–ene click and RAFT polymerisations for the production
of hyperbranched materials. Furthermore, the polymer side-chain functionalities could be easily depro-
tected to yield an active amine which could be subsequently coupled to a drug molecule in good yields.
The resultant amphiphilic copolymers formed a range of unimolecular or kinetically-trapped micellar-like
nanoparticles in aqueous environments, and the non-cationic polymers were all well-tolerated by MCF-7
breast cancer cells. The rapid and facile route to such highly adaptable polymers, as demonstrated here,
oﬀers promise for a range of bio materials applications.
Introduction
Biodegradable synthetic polymer–drug conjugates have been
under active investigation as macromolecular therapeutics for
over 40 years, yet there are still relatively few marketed drugs of
this type.1–4 One major reason for this lack of commercial and
clinical translation has been the diﬃculty in matching the con-
flicting demands of high therapeutic eﬃcacy with ease of
preparation and characterisation. For example, there have
been many examples of synthetic polymer–drug conjugates
which show high activity in vitro and in pre-clinical in vivo
studies.5–8 However, inspection of the structures of some of
these materials suggests they would be challenging to syn-
thesise from a commercial standpoint, or would require exten-
sive toxicological investigations prior to use which would slow
their development.9,10 Accordingly, there remains a focus on
aliphatic polyesters for pharmaceutical applications, as there
are many flexible routes for their synthesis, and the metab-
olites produced upon their breakdown in the body are largely
known and are removed via natural excretory pathways.11–13
Poly(lactide)s (PDLLA), poly(caprolactone)s (PCL) and poly(gly-
colide)s (PGA) and their copolymers are the most widely used
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polyesters in the health care sector, owing to their accessibility
from readily-available monomers, favourable mechanical pro-
perties, hydrolytic degradation and biocompatibility.14–17
Of particular interest are poly(lactide)s and associated copo-
lymers which can be easily synthesised via ROP of D,L-lactide
(LA), a natural recurring cyclic ester. PDLLA is already used in
drug delivery as the hydrophobic block of GenexolP10®, a
PEG-PLA co-polymer formulation of the anti-cancer drug
Paclitaxel,18 currently in the clinic in Korea. However, a major
drawback with lactide-type polymers in advanced therapeutic
applications is the lack of functional ‘handles’ on the
monomer units, resulting in the inability to conjugate drug
molecules to the polymer backbone. This limits the overall
drug loading in the formulation and ultimately the dose which
can be delivered. In addition, limitations in the ability to
control degradation rate, as well as concerns over the long-
term biological eﬀects of tin-based catalysts typically used in
their production,19,20 are driving research eﬀorts towards the
development of more ‘functional’ and adaptable PLA-analogue
polymer therapeutics.
Modification of the starting lactide monomers can be
employed to introduce addressable functionalities along the
polymer main chain.21 However, this strategy often requires
many synthetic steps as well as ineﬃcient purifications
leading to low yields. Another disadvantage is that not all
introduced functionalities are compatible with the ROP
process. Free nucleophiles such as hydroxyls, amines or thiols
cannot be present during polymerisation, and therefore protec-
tion/deprotection and post-polymerisation modifications may
need to be employed if drugs are to be linked to the polymers.
In this regard, aliphatic poly(carbonate)s are advantageous, as
there are a range of methods for their derivatisation, and the
central polymer backbone has appropriate properties for bio-
medical applications, being well-tolerated in the body and also
biodegradable.22 In addition, main-chain substituted polycar-
bonates can be synthesised from functionalised cyclic carbon-
ate monomers through relatively simple chemistry, thus allow-
ing ready access to covalently-linked polymer–drug
conjugates.23
There are now several reports that both lactide and cyclic
carbonate monomers can be ring-opened under ambient con-
ditions with organocatalysts, such as 1,8-diazabicyclo[5.4.0]
undec-5-ene (DBU),24–27 thus negating the need for metal cata-
lysts or high temperatures which might otherwise generate
toxic or degraded components in the final polymer product.
These data suggest that functionalised materials which are (a)
biodegradable and (b) adaptable for a variety of therapeutic
formats might be produced through ring-opening polymeris-
ations of carbonates under mild reaction conditions. These
chemistries might also serve to generate ‘platform’ polymer–
drug conjugates which can be optimised for specific drug
delivery applications by further end-group or side-chain modi-
fications. For example, by utilising PEG chains of varying
lengths and architectures as initiators, amphiphilic PEG-poly
(caprolactone) co-polymers which self-assemble into long-cir-
culating nanoparticles can be envisaged. Importantly, the
adoption of bifunctional initiators provides additional oppor-
tunities to produce biodegradable copolymers with hybrid
architectures by using the ω-functionality in a second synthetic
step, such as ATRP or RAFT polymerisations, or Michael
addition reactions.28
In this work we report the synthesis of a small library of
mixed-polyester–polycarbonate materials with potential appli-
cations in polymer therapeutics (Fig. 1).
The route involved preparation of a BOC-protected cyclic
carbonate monomer (tBSC) derived from serinol, followed by
ROP with lactide, initiated by a range of nucleophiles, to gene-
rate the multi-architecture functional materials. The diﬀerent
PEG-based initiators were chosen to tune the amphiphilic
balance of the final block-copolymer chain (keeping the hydro-
phobic block length constant), in order to produce polymers
capable of self-assembly into nanoparticles with a range of
sizes. To highlight further the versatility of the approach, a
methacrylate initiator was employed to generate an end-group
used in tandem ROP-thiol–ene “click” and ROP-RAFT poly-
merisations, thus forming amphiphilic hyperbranched poly-
mers with diﬀerent sizes. In addition, after deprotection of the
BOC groups on the polycarbonate component of the materials,
the resultant amine functionality was exploited to link with
doxorubicin via a urea group as a proof of concept for drug
conjugation. Finally, the polymer library was evaluated for
eﬀects on a model cell line as the first steps towards practical
drug delivery applications.
Experimental section
Materials
All chemicals were used as obtained without additional purifi-
cation unless otherwise stated. Poly(ethylene glycol) methyl
ether (Mn = 5000/2000 Da), trimethylolpropane ethoxylate
(3PEG, 4/15 EO/OH, Mn = 1014 Da), pentaerythritol ethoxylate
(4PEG, 15/4 EO/OH, Mn = 797 Da), 1,8-diazabicyclo[5.4.0]
undec-5-ene (DBU, 98%), triethylamine (TEA, ≥99%), 4-amino-
fluorescein, di-tert-butyldicarbonate (99%), 4-(hydroxymethyl)
phenylboronic acid pinacol ester (97%), and extra-dry DMSO
were purchased from Sigma-Aldrich. Polyethylene glycol (PEG,
average Mn = 4000 Da) was purchased from Fisher Chemical.
2-Amino-1,3-propanediol (Serinol, 98%) and dichloromethane
(DCM, 99.8%, extra dry over molecular sieve, stabilised,
Acroseal) were purchased from AcrosOrganics. Trifluoroacetic
acid (TFA, 99%) was purchased from VWR Chemicals.
Ethylchloroformate was purchased from Merck KGaA.
Synthesis of tert-butyl (1,3-dihydroxypropan-2yl) carbamate
(tert-butyl serinol, tBS)
Serinol (10 g, 110 mmol) was dissolved in a mixture of water
and tetrahydrofuran (THF) (100 ml, 4 : 1 v/v) and the solution
was cooled to 0 °C. Following addition of triethylamine
(22.5 mL, 162 mmol), to this mixture di-tert-butyl dicarbonate
(29 g, 131.5 mmol) pre-dissolved in THF (20 mL) was added
dropwise over 1 h. The reaction mixture was left stirring over-
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night at room temperature. Subsequently, THF was removed
under reduced pressure and the residue was extracted with
ethyl acetate (4 × 100 mL). The colourless organic phase was
dried over anhydrous magnesium sulphate and concentrated
under reduced pressure. The crude product was recrystallized
in ethyl acetate (yield 70%, 14.7 g). 1H NMR (400 MHz, CDCl3,
ppm): δ 5.30 (s, 1H), 3.86–3.63 (m, 5H), 2.60 (s, 2H),
1.45 (s, 12H). Observed chemical shifts and integrals were in
agreement with previous reports.29
Synthesis of tert-butyl (2-oxo-1,3-dioxan-5-yl) carbamate:
(tert-butyl serinol carbonate, tBSC)
Tert-Butyl (1,3-dihydroxypropan-2yl) carbamate (26.0 g,
136 mmol) and ethyl chloroformate (32.0 g, 295 mmol) were
dissolved in THF (140 mL) and the solution was cooled to
0 °C. Triethylamine (47.0 mL, 338 mmol) was then added
dropwise over 1 h. Subsequently, the reaction mixture was left
stirring overnight at room temperature. The precipitated salts
were filtered oﬀ and the filtrate was concentrated under
reduced pressure to aﬀord the product as a white solid. The
product was left drying in a vacuum oven overnight and sub-
sequently washed with a mixture of THF : Et2O (2 : 8, v/v) to
remove traces of unreacted starting materials (yield 65%,
19.20 g). 1H NMR (400 MHz, CDCl3, ppm): δ 5.30 (s, 1H), 4.55
(d, 2H), 4.45 (d, 2H), 4.10 (s, 1H), 1.45 (s, 9H). Observed chemi-
cal shifts and integrals were in agreement with previous
reports.29,30
PEGylated initiated ring-opening polymerisation of lactide and
tert-butyl (2-oxo-1,3-dioxan-5-yl) carbamate (tBSC): kinetics in
presence of DBU
A predetermined amount of PEGylated chain initiator
(mPEG2000, mPEG5000, PEG4000, tPEG1014 or pPEG797), lactide
and tBSC were weighed out in a glass vial (dried in an oven at
100 °C overnight) and capped with a rubber stopper. [M]/[I]
was adjusted in order to maintain a constant length of hydro-
phobic chains across the diﬀerent final architectures. Dry
DCM (5 mL), was added and the mixture was allowed to dis-
solve at room temperature. An aliquot was taken of the
monomer–initiator mixture at this point: this sample was
denoted as at time point t0. DBU (3% mol/mol compared to
the total amount of monomers) was dissolved in DCM (1 mL)
and added to catalyse the ring opening process. After
reaction, the catalyst was deactivated through adding the
polymer mixture, dropwise, to cold hexane (30 mL) and the
polymer was purified via multiple precipitation steps and
dried in a vacuum oven (conversion of monomer into
polymer ∼75–80% w/w). The purified materials were analysed
by NMR and GPC. 1H NMR (mPEG5000-(LA)50-(tBSC)50 as
model) (400 MHz, CDCl3, ppm): δ 5.19 (broad m, 104H),
4.26 (broad m, 249H), 3.66 (broad s, 492H), 3.39 (s, 3H),
1.82–1.46 (2 asymmetric broad s, 429 + 35H), 1.59 (broad m,
314H). 13C NMR (101 MHz, CDCl3, ppm) δ = 169.76,
154.50, 70.57, 69.00, 67.97, 65.58, 30.93, 28.33, 25.61, 16.65,
15.28.
Fig. 1 Synthetic strategy towards multicomponent amphiphilic copolymers and key characterisation outputs.
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PEGylated initiated ring-opening polymerisation of sequential
block copolymer of lactide and tert-butyl (2-oxo-1,3-dioxan-5-yl)
carbamate (tBSC): kinetics in presence of DBU
A predetermined amount of PEGylated chain initiator
(PEG4000) and lactide were weighed out in a glass vial (dried in
an oven at 100 °C overnight) and capped with a rubber
stopper. Dry DCM (5 mL), was added and the mixture was
allowed to dissolve at room temperature. Aliquots were taken
and polymerisation carried out as described for the mPEG-OH
reaction. After polymerisation, the catalyst was deactivated
through adding the polymer mixture, dropwise, to cold hexane
(30 mL) and the polymer was purified via multiple precipi-
tation steps and dried in a vacuum oven to obtain PEG4000-
(LA)50 (P6). The resultant macroinitiator and (tBSC) was
weighed out in a glass vial, and the polymerisation carried out
as above to achieve the chain extension. After 15 minutes of
reaction time, the catalyst was deactivated through adding the
polymer mixture, dropwise, to cold hexane (30 mL) and the
polymer was purified and dried as before to obtain PEG4000-
(LA)50-b-(tBSC)15 (P7) (conversion of monomer to polymer
∼75–80% w/w). A final NMR spectrum was recorded of the pro-
ducts post purification. 1H NMR (400 MHz, CDCl3, ppm):
δ 5.19 (broad m, 94H), 4.28 (broad m, 68H), 3.67 (broad s,
356H), 1.65–1.47 (2 asymmetric broad s53 + 78H), 1.61
(broad m, 280H). 13C NMR (101 MHz, CDCl3, ppm) δ = 169.53,
154.52, 70.57, 69.02, 66.03, 31.22, 16.66.
(2-Hydroxyethyl)methacrylate initiated ROP of lactide and
(tBSC) in presence of DBU
The desired amounts of cyclic monomers and HEMA-initiator
were weighed into a vial (dried in an oven at 100 °C overnight).
The initiator was stored under anhydrous conditions.
Subsequently, the vial was capped using a rubber stopper, and
DCM, dried over molecular sieves and kept under an inert gas
environment, was added and the mixture was allowed to dis-
solve properly (at RT) for 5–10 minutes. The catalyst was added
at 1.5% mol/mol compared to the amount of monomer to
trigger the ring opening process. After 15 minutes of reaction
time, the catalyst was deactivated through adding the polymer
mixture, dropwise, to cold diethyl ether (20 mL) and the
polymer was purified via multiple precipitation steps and
dried in a vacuum oven to obtain the final macromonomer
(conversion of monomer into polymer circa 75–80% w/w).
A final NMR spectrum was recorded of the product post
purification.
Thiol–ene “click” chemistry of macromonomers
HEMA-(LA)15-(tBSC)15 (P8) (15 mg) was dissolved in 30 µL of
DMSO-d6. 2,2-Dimethyl-2-phenyl acetophenone (DMPA)
(25 μL aliquot of a 40 mg mL−1 solution in DMSO-d6) and
benzyl mercaptan (5 equiv.) were added and the reactions were
then irradiated by UV at 365 nm for 30 minutes. The modified
macromonomer was purified by precipitation into cold diethyl
ether (5 mL) and dried. A final NMR spectrum was recorded of
the product post purification.
RAFT polymerisation of macromonomers
Hyperbranched random copolymers with PEGMA
(HB-PEGMA-(HEMA-(LA)15-(tBSC)15). PEGMA (HB1, 90 mol%:
142 mg, 0.473 mmol) or (HB2, 80 mol%: 126 mg,
0.421 mmol), HEMA-(LA)15-(tBSC)15 (HB1, 10 mol%: 100 mg,
0.0526 mmol) or (HB2, 20 mol%: 200 mg, 0.105 mmol),
EGDMA (5.21 mg, 0.0263 mmol) RAFT (8.93 mg, 0.0263 mmol)
and AIBN (0.9 mg, 5.26 µmol) were dissolved in 750 µL THF in
a 2 mL reaction vessel equipped with a magnetic stirrer bar
and sealed with a rubber septa reinforced with a cable tie. The
solution was bubbled with argon for 20 minutes and then
stirred at 70 °C overnight. The reaction mixture was then preci-
pitated into hexane and the polymer was analysed by 1H NMR
and SEC. 1H NMR (400 MHz, DMSO) δ 7.21–7.35, (broad m,
5H), 6.99–7.13 (broad s, 1H), 5.02–5.31 (broad m, 2H),
4.14–4.45 (broad s, 5H), 4.04–4.15 (broad s, 2H), 3.26–3.75
(broad s, 4H), 1.53–1.65 (broad m, 3H), 1.46 (broad s, 9H),
2.05–0.42 (broad, m, 8H, CH2 and CH3 of polymer backbone
and CHCH3).
Chain extended hyperbranched random copolymer with
PEGMA (HB3, HB-70PEGMA-30(HEMA-(LA)15-(tBSC)15)). A two-
step polymerisation was carried out to form a larger sized HB.
PEGMA (70 mol%: 110 mg, 0.368 mmol), HEMA-(LA)15-
(tBSC)15 (30 mol%: 300 mg, 0.158 mmol), EGDMA (5.21 mg,
0.0263 mmol) RAFT (8.93 mg, 0.0263 mmol) and AIBN
(0.9 mg, 5.26 µmol) were dissolved in 750 µL THF in a 2 mL
reaction vessel equipped with a magnetic stirrer bar and
sealed with a rubber septa reinforced with a cable tie. The
solution was bubbled with argon for 20 minutes and then
stirred at 70 °C overnight. The reaction mixture was then preci-
pitated into hexane, and the resultant polymer was sub-
sequently chain extended with additional PEGMA. 30 mol%
LA-tBSC HB (50 mg, 0.0167 mmol), PEGMA (100 mg,
0.333 mmol) and AIBN (0.2 mg, 1.67 µmol) were dissolved in
400 µL THF in a 2 mL reaction vessel equipped with a mag-
netic stirrer bar and sealed with a rubber septum reinforced
with a cable tie. The solution was bubbled with argon for
20 minutes and then stirred at 70 °C for 6 h. The reaction
mixture was then precipitated into hexane and HB3 was ana-
lysed by 1H NMR and SEC. 1H NMR (400 MHz, DMSO) δ
7.21–7.35, (broad m, 5H), 6.99–7.13 (broad s, 1H), 5.02–5.31
(broad m, 2H), 4.14–4.45 (broad s, 5H), 4.04–4.15 (broad s,
2H), 3.26–3.75 (broad s, 4H), 1.53–1.65 (broad m, 3H), 1.46
(broad s, 9H), 2.05–0.42 (broad, m, 8H, CH2 and CH3 of
polymer backbone and CHCH3).
BOC deprotection optimisation
A predetermined amount of PEGylated copolymer (P2, 100 mg,
0.46 mmol in carbonate-BOC monomer) was dissolved in extra
dry DCM (3 mL). The TFA optimum amount was found to be
5 eq. with respect to the calculated tBSC units (2.3 mmol,
263 mg) and was added slowly to the polymer mixture at 0 °C.
The reaction mixture was left stirring for varying amounts of
time (5, 10 and 30 min) and following precipitation in cold
hexane, was washed with cold diethyl ether and analysed by
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1H-NMR. Diﬀerent degrees of deprotection were achieved by
simply varying the reaction time and at the same time polymer
main backbone degradation was avoided. 1H NMR (t = 0 min)
(400 MHz, DMSO-d6) δ = 5.26–5.10 (m, 80H), 4.17–4.01 (m,
168H), 3.52 (s, 492H), 1.48 (s, 240H), 1.39 (s, 370H). 1H NMR
(after 30 min and post purification and drying) (400 MHz,
DMSO-d6) δ = 8.42 (bs, 30H), 7.18–7.02 (m, 34H), [around 10
units deprotected] 5.24–5.11 (m, 62H), 3.51 (s, 492H),
1.55–1.41 (m, 204H), 1.38 (s, 320H).
Doxorubicin coupling procedure
N,N′-Disuccinimidyl carbonate (DSC) (1.5 eq. with respect to
the amount of doxorubicin, 0.125 mmol, 32 mg) pre-dissolved
in anhydrous MeCN (3 mL) was added to a solution of doxo-
rubicin (1.0 eq., 0.083 mmol, 48 mg) in dry DMSO (3 mL) at
0 °C. TEA (2.5 eq. with respect to the amount of doxorubicin,
0.21 mmol, 30 μL) was added slowly to the reaction mixture
and left stirring for 4–5 hours. Deprotected polymer
(mPEG5000-(LA)50-(tBSC)50; 1.0 eq., 0.083 mmol, 15 mg;
equivalents were calculated to be in high excess when com-
pared to each repeating tBSC unit) was dissolved in a mixture
of anhydrous MeCN/dry DMSO (50/50, v/v, 3 mL) and TEA (2.0
eq. with respect to the amount of deprotected polymer,
0.166 mmol, 23 μL) was added, and the solution was sub-
sequently added dropwise to the previous reaction mixture.
The reaction was left stirring for a further 3 hours at 0 °C. The
resultant conjugated polymer was purified through multiple
precipitation steps in cold hexane : diethyl ether (1 : 5 v/v)
mixture and dialysed against water : methanol (5 : 1 v/v)
mixture for 24 h. Finally, the purified aqueous suspension was
freeze-dried for 48 h and stored at −22 °C. A final NMR spec-
trum of the product (mPEG5000-(LA)50-(tBSC)50-DOXO) post
purification and completely dried was recorded. 1H NMR
(400 MHz, DMSO-d6) δ = 14.08 (s, 4H), 7.93 (d, J = 4.3 Hz, 8H),
7.69–7.65 (m, 4H), 7.63 (s, 4H), 7.07 (d, J = 7.1 Hz, 21H), 5.34
(d, J = 8.7 Hz, 8H), 5.24–5.11 (m, 78H), 4.86 (d, J = 5.9 Hz, 4H),
4.61–4.56 (m, 4H), 4.50 (d, J = 10.1 Hz, 8H), 4.36 (d, J = 4.0 Hz,
12H), 4.16–3.93 (m, 205H), 3.81–3.74 (m, 8H), 3.71–3.66 (m,
4H), 3.51 (s, 492H), 3.24 (s, 4H), 3.07–3.01 (m, 8H), 2.94 (d, J =
5.9 Hz, 4H), 2.23 (d, J = 3.8 Hz, 4H), 1.50–1.41 (m, 200H), 1.38
(s, 290H).
Nanoparticle preparation
A nanoprecipitation method was used to form nanoparticles,
whereby the polymers (10 mg) were dissolved in acetone
(1 mL). The polymeric solution was added dropwise to de-
ionized water (10 mL, final concentration of 1 mg mL−1),
under constant stirring at 550 rpm. The polymers rapidly
formed nanoparticle suspensions through solvent exchange
between water and acetone. The final suspension was then left
stirring overnight at room temperature in order to reach com-
plete acetone evaporation.
Critical aggregation concentration (CAC) calculation
The critical aggregation concentration (CAC) was calculated
using a Zetasizer Nano ZS as described in Malvern application
note AN101104 (http://www.malvern.com/en/support/resource-
center/application-notes/AN101104SurfactantMicelleCharacteri-
zation.aspx). In brief, a constant attenuator was selected and
the intensity of the scattered light (count rate in kcps) was
monitored for a range of diluted NP suspensions
(100–0.05 μg mL−1).31 The intensity increases linearly with
concentration above the CMC, while below the CMC the count
rates reach a plateau. The CMC was then calculated by inter-
secting the two lines.
4-Aminofluorescein encapsulation study
Polymer (10 mg) was dissolved in acetone (1 mL). An aliquot
(0.5 mL) of a stock solution of 4-aminofluorescein (5.27 mg
dissolved in 3.30 mL acetone) was added to the polymer. This
was then added dropwise to PBS (10 mL) under constant stir-
ring at 550 rpm. After 3 hours, nanoparticle colloidal suspen-
sions were left to dialyse in water for 4 days.
HB-PEGylated copolymers coprecipitation
Polymers P2 or P5 (10 mg) were dissolved in acetone (1 mL)
and polymer HB2 (10 mg) was added to the organic solution.
The final solutions containing both the PEGylated copolymers
and HB materials were then added dropwise to PBS (10 mL)
under constant stirring at 550 rpm. After complete acetone
evaporation DLS analysis was performed to evaluate the aggre-
gation state of the final colloidal systems. As a control, the two
suspensions (copolymers alone and HB alone) prepared in two
separate precipitations steps were mixed directly in the DLS
cuvette (0.5 mL each).
Eﬀects of polymer formulations in breast cancer cells
The lactate dehydrogenase (LDH) release assay and
PrestoBlue™ Cell Viability assays were performed to assess the
eﬀects of nanoparticles on a model cell line. MCF7 breast
cancer cell line was obtained from American Type Culture
Collection (ATCC) and cultured in passage window of 15. Cells
were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS), 0.1 mg
ml−1 streptomycin, 100 units per ml penicillin, 0.25 µg ml−1
amphotericin and 2 mM L-glutamine. The cells were seeded at
1 × 104 cells per well in 96 well plates and cultured for
24 hours prior to assaying. Nanoparticles were exposed to cells
for 4, 24 or 48 hours and applied in 100 µL phenol red free
DMEM containing 10% (v/v) FBS and 2 mM L-glutamine.
Triton X-100 applied at 1% (v/v) applied in phenol red free
medium was used as a cell death (positive) control and a
vehicle control containing no nanoparticles used as a negative
control. Following exposure, 50 µL of supernatant was col-
lected per well for analysis of LDH content. Cells were then
washed twice with warm PBS and 100 µL 10% (v/v) PrestoBlue
reagent diluted in phenol red free medium applied per well for
60 minutes. The resulting fluorescence was measured at 560/
600 nm (λex./λem.). Relative metabolic activity was calculated by
setting values from the negative control as 100% and positive
control values as 0% metabolic activity. Assessment of LDH
release was performed according to the manufacturer’s
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instructions and involved adding 100 µL LDH detection
reagent to the collected supernatant samples and incubating
at room temperature shielded from light for 25 minutes.
Absorbance was then measured at 492 nm. Relative LDH
release was calculated with the negative control absorbance at
492 nm taken as 0%, and the positive control, assumed to
cause total cell lysis, as 100%.
General methods and instrumentation
Nuclear magnetic resonance. Bruker AV400 and AV3400
NMR spectrometers operating at 400 MHz (1H) and 101 MHz
(13C) at ambient temperature were used to perform nuclear
magnetic resonance (NMR) analysis in deuterated solvents.
Chemical shifts were assigned in parts per million (ppm). 1H
NMR chemical shifts (δH) are reported with the shift of CHCl3
(δ = 7.26 ppm) as the internal standard when CDCl3 was used.
13C Chemical shifts (δC) are reported using the central line of
CHCl3 (δ = 77.0 ppm) as the internal standard. All spectra were
obtained at ambient temperature (22 °C ± 1 °C). MestReNova
6.0.2 copyright 2009 (Mestrelab Research S. L.) was used for
analysing the spectra.
Mass spectrometry. High Resolution Mass spectrometry
(HRMS) was conducted using a Bruker MicroTOF spectrometer
operating in electrospray ionisation (ESI) mode.
Fourier-transform infra-red spectroscopy. FTIR spectroscopy
was performed in the range of 4000–650 cm−1. This was
carried out using a Bruker Tensor 27 FT-IR spectrophotometer
using an ATR attachment. Spectra were analysed using
MicroLab software.
Gel permeation chromatography (GPC). Gel permeation
chromatography (GPC) was used for determination of number
average molecular weight (Mn), weight average molecular
weight (Mw), peak molecular weight (Mp) and molecular
weight distribution (polydispersity, Đ, Mw/Mn). The analysis
was performed using an Agilent 1260 Infinity Series HPLC
(Agilent Technologies, USA) fitted with two Agilent PL-gel
Mixed-E columns in series at a flow rate of 1 mL min−1 using
THF (HPLC grade, Fisher Scientific) as eluent at room temp-
erature and a diﬀerential refractive index detector (DRI); or a
PL50+Polymer Laboratories system equipped with a refractive
index detector, employing 2 mixed bed (D) columns at 50 °C
and using a solution of DMF 0.1% LiCl as mobile phase at a
flow rate 1 mL min−1. Poly(methyl methacrylate) standards (Mn
range: 1 800 000–505 g mol−1) and polycaprolactone standards
were used for calibration.
Diﬀerential scanning calorimetry (DSC). Thermal properties
of the materials were studied by diﬀerential scanning calori-
metry (DSC) (Q2000, TA Instruments, Leatherhead, UK) at a
heating rate of 10 °C min−1.
Thermal gravimetric analysis (TGA). TGA analysis was per-
formed in the temperature range of 30–400 °C at 10 °C min−1
(TGA5500). The data were analysed using Thermal Analysis
Software (TRIOS).
Dynamic light scattering (DLS). The particle size and zeta-
potential were analysed by dynamic light scattering (DLS)
using a Zetasizer Nano ZS (Malvern Instruments Ltd).
Measurements were taken in triplicate of NPs suspensions at
1 mg mL−1 in milliQ water and used to calculate average inten-
sity particle size distributions.
Transmission electron microscopy (TEM). TEM samples
were prepared as follows; the sample in aqueous suspension
(13 μL) was added to a copper grid (Formvar/carbon film
200 mesh copper (100)). The sample was left on the grid for
10 min and then the excess was removed using filter paper.
The grid was allowed to dry under a fume hood for a
minimum of 30 min prior to use. TEM images were captured
using the FEI Biotwin-12 TEM equipped with a digital camera
at the Nanoscale and Microscale Research Centre (NMRC) of
the University of Nottingham.
Results and discussion
The key steps in the syntheses were preparation of a side-chain
functional cyclic carbonate monomer, and ring-opening poly-
merisations with organic catalysts under mild conditions to
generate materials with a range of architectures and self-
assembly properties.
Monomer synthesis and purification
The cyclic carbonate monomer was prepared by adapting a
previously reported two-step synthesis.32 The key modification
was the removal of chromatographic purification steps in the
monomer synthesis by a simple solvent/non solvent (THF/Et2O)
wash step. The final unoptimised yield of pure monomer was
65% after this rapid and simplified synthetic route (Fig. S1†).
Polymer syntheses – statistical co-polymers with polyester and
polycarbonate hydrophobic blocks
Five diﬀerent PEGylated initiators were adopted to produce
polymers with diﬀerent final architectures, but the same
overall length of hydrophobic unit, which in this case was a
random copolymer of lactide and tBSC. It was observed via
NMR kinetics experiments that both monomers were con-
sumed to >90% conversion within 15 minutes (Fig. S2†), and
therefore this was chosen as the reaction time for all the PEG-
initiated polymerisations. As depicted in Fig. 2, all of the final
polymers showed the characteristic NMR peaks of polymerised
lactide and tBSC, with good agreements in the feed ratios of
both monomers and the initiator (Fig. S3,† mPEG5000-(LA)50-
(tBSC)50 as model, P2 entry). In addition, in the ATR-IR
spectra, all the characteristic transitions of both ester and car-
bonate moieties were observed (Fig. S4†), further confirming
the successful copolymerisation. There was no observed diﬀer-
ence in reactivity across the series of PEGylated initiators, as
demonstrated by the final molecular weights and monomer
ratios reached post-purification (Table 1) (Scheme 1).
In the DSC thermograms, as reported in Table 1, the poly-
mers synthesised using crystalline PEG initiators showed a
melting point (with diﬀerent values of enthalpy) in the first
cycle, while no melting transition could be observed in sub-
sequent cooling and heating cycles within the temperature
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range explored. Glass transition temperatures (Tg) were
observed for all the polymeric samples indicating the presence
of amorphous structures as previously reported for similar
copolymers such PEG-PLGA and PLGA.33,34
The inability of the PEG chain to recrystallise can be attrib-
uted to the interaction with the ester-carbonate hydrophobic
chains, hindering the chain-packing nucleation steps during
cooling cycles.35 In addition, it was found that the polymers
synthesised from PEG initiators which were liquid at room
temperature (i.e. the 3 and 4 arms PEG, P4 and P5 entries) had
no determinable melting point. Furthermore, Thermal
Gravimetric Analysis (TGA), demonstrated that the five copoly-
mers were thermally stable up to 160–180 °C. Above this temp-
erature, a steep loss in mass occurred up to 90% of the initial
sample (P2 and P3 copolymer showed a loss around 70%
attributed to a higher thermal stability), with the end of the
transition at around 240–260 °C (Fig. S5†). During this
thermal transition, two degradation steps can be observed
(Fig. S5†) after the derivative analysis (Fig. S5† inset). These
two thermal degradation transitions are likely to be related to
Fig. 2 (A) general reaction scheme for the PEG-initiated ROP, (B) 1H NMR spectra of the ﬁve copolymers (with random distribution of ester and car-
bonate units) and (C) GPC traces of the polymers.
Table 1 Chemical and physical characterisation of the PEGylated copolymers
LA-tBSC units
(targeted)
LA-tBSC
units (exper) Mn (NMR)
Mn
a
(GPC) kDa Đ
Tg
(°C)
Tm1
(°C)
Tm2
(°C)
ΔH1
(J g−1)
P1. mPEG2000-(LA)50-(tBSC)50 60–53 55–48 20 330 20.3 1.26 43.1 39.6 — 5.5
P2. mPEG5000-(LA)50-(tBSC)50 55–50 52–50 23 200 23.3 1.15 18.6 45.2 — 31.7
P3. PEG4000-(LA)50-(tBSC)50 50–50 50–45 20 960 17.0 1.22 20.6 42.1 — 25.6
P4. 3 armPEG1014-(LA)50-(tBSC)50 55–53 52–49 19 135 16.4 1.21 46.4 — — —
P5. 4 armPEG797-(LA)50-(tBSC)50 55–55 55–55 20 650 16.3 1.22 42.1 — — —
P6. PEG4000-(LA)50 50–— 50–— 11 200 10.2 1.05 42.2 49.2 — 21.0
P7. PEG4000-(LA)50-b-(tBSC)15 50–15 50–13 14 020 13.6 1.18 n.d. 41.2 — 26.2
a Compared to PMMA standards.
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lactide (∼30% weight loss) and carbonate (∼50% weight loss),
respectively, due to the final amount in weight in the poly-
mers. The higher weight retention of P2 and P3 copolymers
has been attributed to the higher weight contribution of the
PEG chains with a net initial weight degradation transition
with an onset at above 300 °C, typical of longer PEG chains.36
The similar thermal degradation profiles of the five copoly-
mers highlighted the similarity in properties of the main ester-
carbonate fragment.
End group fidelity, block copolymer extension and hybrid
polymer architectures via mixed methacrylate-polyester-co-
polycarbonates
To confirm both the presence and fidelity of the hydroxyl end
group following the polymerisations, as well as increase the
range of polymeric architectures achieved, a chain extension
reaction was carried out from a PEG4000-poly(lactide) polymer.
Accordingly, 50 units of lactide as the first monomer were
polymerised and the interim structure confirmed by NMR and
GPC following purification (Fig. S6†). Subsequently, the resul-
tant PEG-lactide macroinitiator (P6) was further reacted with
tBSC to form the block copolymer (P7). The successful attain-
ment of the A–B–C block was certified by NMR, GPC and
ATR-IR of the final material, which demonstrated that no
unanticipated side-reactions occurred during the DBU cata-
lysed polymerisation (Fig. S6†). As expected, the chain exten-
sion of the PEG-lactide A–B polymer, P6, with the carbonate to
form the A–B–C copolymer, P7, modified the thermal response
of the final materials, as seen in the DSC thermograms, where
the melting point of the first cycle shifted over 7 °C (from
49–42 °C) (Table 1). No melting transitions were observed for
either P6 or P7 in the second thermal cycle.
Further confirmation of end-group fidelity, but in this
case from the initiating end of the polymer, was carried out by
preparing a mixed ester-carbonate macromonomer using
2-hydroxyethylmethacrylate (HEMA) as the initiator (Scheme 2).
Therefore, HEMA was employed as an initiator to synthesise
random mixed ester-carbonate macromonomers targeting
final DPn values of 15 for LA and for tBSC. The reactions
reached conversions of >90% within 15 minutes with no side-
reactions as indicated by NMR (Fig. S7†). The expected reten-
tion of methacrylate functionality was demonstrated by a
radical thiol–ene “click” reaction of the P8 macromonomer
with benzyl mercaptan as the model thiol. The macro-
monomer was reacted with 5 equivalents of the thiol with
DMPA as photoinitiator, followed by irradiation at 365 nm for
30 minutes.37,38
Complete conversion of the vinyl groups into the thioether
product was achieved as confirmed by the 1H NMR spectra
(Fig. S8†), marked by the disappearance of the vinyl protons
(between 5.7–6.1 ppm) and the appearance of the diagnostic
benzyl protons (7.2–7.4 ppm).
The extension of the mixed methacrylate polyester-carbon-
ate platform into single-chain nanoparticles was subsequently
investigated owing to the many potential applications of these
systems in diagnostic and therapeutic applications.39–41 The
HEMA-(LA)15-(tBSC)15 macromonomer was copolymerised with
the hydrophilic monomer poly(ethyleneglycolmethacrylate)
(PEGMA) in the presence of a bifunctional cross linker (ethyle-
neglycoldimethacrylate, EGDMA) at 10, 20 and 30 mol% with
Scheme 1 Synthesis of monomer and PEG-initiated copolymers of varying architectures and block compositions.
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respect to PEGMA. The 10 and 20 mol% monomer compo-
sition resulted in branched particles, HB1 and HB2, that
retained their aqueous solubility and with sizes of ∼13 nm and
∼15 nm respectively. However, the 30 mol% monomer compo-
sition was insoluble in water, and thus was further chain
extended with additional PEGMA until the water-
soluble polymer HB3 was produced, which displayed a
final particle size of 30 nm. As for the linear polymers, GPC
analysis confirmed a single polymeric population in all cases
(Fig. 3).
Nanoparticle formation and dye encapsulation
Self-assembling amphiphilic PEG-polylactide and PEG-polycar-
bonate materials have been widely investigated as nanoparticle
carriers in drug and gene delivery assays.42,43 Therefore, we
screened the ability of the varying architecture polymers syn-
thesised above to self-assemble into well-defined nanoparticles
using the standard formulation technique of nanoprecipita-
tion (solvent displacement).44 Rapid precipitation of the block
polymers from acetone solutions into MilliQ water resulted in
Scheme 2 The overall reaction steps of the production of labile-ester initiated copolymer, from monomer synthesis to the formation of varying
hyperbranched polymers.
Fig. 3 (A) 1H NMR spectra of the hyperbranched random copolymers synthesised in presence of PEGMA by RAFT polymerisation, (B) GPC traces of
the polymers and (C) DLS traces of the unimolecular hyperbranched nanoparticles.
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formation of nanoparticles with sizes varying from 70–144 nm
(Table 2).
To probe further the structures of the nanoparticles, repre-
sentative samples were also imaged by TEM. The size ranges
observed in the images were similar to those obtained by DLS,
taking into account the normal compaction following the TEM
drying process (Fig. S9†). Although the chain architectures
were slightly diﬀerent across the polymer series from P1 to P5,
the morphologies of all the self-assembled systems were
approximately spherical, with no evidence of worm-like
micelles or other altered geometry superstructures. Further
detail in structure was not observable from the micrographs
owing to the limits in contrast obtained from non-stained
samples and the resolution of the images. However, based on
the ratios of hydrophobic to hydrophilic blocks, micelle-like
nanoparticles would be expected to form under the conditions
we employed, with vesicles or ‘worms’ only likely at higher
polylactide and polycarbonate mole fractions owing to packing
parameter constraints. The zeta potentials of all these nano-
particles were negative, below −10 mV, as expected based on
the presence of a hydrophilic PEG corona shell and the weak
lone-pair cation interactions at the oxyethylene units and the
corresponding association of anions to form the outer layers
(Table 2). The length of the hydrophobic fragments was kept
constant across the range of copolymers, and thus the diﬀer-
ences in size and zeta potential can be attributed to the
diﬀerent PEGylated initiators adopted. It was apparent that the
A–B polymers based on PEG-lactide resulted in nanoparticles
of a smaller size compared to the random copolymers, while
the chain extended A–B–C block copolymer formed larger par-
ticles, perhaps due to diﬃculties in packing with the bulkier
BOC-carbonate fragments (Fig. S10†). Critical Aggregation
Concentration (CAC) values were calculated by exploiting the
light scattering count rate intensity variation according to
serial dilution experiments. The resulting values were in the
range of 8.5 to 12.7 µg ml−1 which indicated that NPs were
present at low concentration in the final suspensions and
required high dilution before disaggregation occurred
(Fig. S11†).
Well-defined nanoparticles have also been formed using
branched polymers encapsulated within A–B linear copoly-
mers, and their self-assembly and colloidal properties have
been extensively studied previously.45,46 We therefore selected
polymers P2 and P5 as the model PEGylated copolymers (one
linear and one branched) to encapsulate HB2 through a co-
nanoprecipitation step. DLS analysis of the individual NPs/
HBs in aqueous solution showed a single population, and the
control mixed solution of P2 + HB2 and P5 + HB2 showed two
populations corresponding to the individual components as
expected. Importantly, the co-nanoprecipitation systems
showed only a single DLS peak, confirming that the HBs were
able to be entrapped within the larger NPs (Fig. 4).
A second indicator of self-assembly, and a guide to utility in
biomedical delivery applications, was the ability of the nano-
particles to encapsulate a probe or drug molecules. The
polymer nanoparticles were thus screened for encapsulation of
the dye 4-aminofluorescein in a preliminary assay. For these
encapsulation experiments we selected the linear co-polymers
and the star polymers P1–P5, in order to evaluate in the first
instance the compatibilities of the PEG-poly(lactide)-poly(car-
bonate) ‘parent’ structures with a model drug. In Fig. S12† it
can be seen that the star branched PEGylated copolymers,
namely P4 and P5, encapsulated more of the dye than the
other polymers, in agreement with data reported previously
with similar materials.47–49
Polymer side-chain derivatisation and drug coupling
The intended use of the polymer family as delivery agents was
also envisaged in which drugs were covalently attached as well
as or in place of encapsulated therapeutics. Accordingly,
polymer P2 was again chosen as the exemplar material, from
the small library and activated for drug attachment by removal
of the BOC group. It was important for this step to occur
without causing degradation of the polyester and polycarbo-
nate backbone, thus the reaction was performed at 0 °C. In
experiments to evaluate the optimal timing of the reactions, it
was found that consistent deprotection of up to 30% of the
initial BOC functionality was reached within 30 minutes of
reaction, without degradation of the polymer backbone as
shown by NMR (Fig. 5). It was also found that removal of the
BOC group and formation of free amine groups on the side-
chains reduced the solubility of the polymer in CDCl3, thus all
the deprotected materials were analysed in DMSO-d6 (for
clarity also the unfunctionalized polymer was analysed in both
the deuterated solvents as shown in Fig. S13†). As depicted in
Fig. 3, the NH of the carbamate and the protons of the new
produced ammonium moieties were clearly visible in the
spectra between 7.0 and 8.6 ppm thus allowing simple calcu-
Table 2 Nanoparticle size distribution and zeta potential
Sizea (nm) (at 500 µg ml−1) Z-potentialb (mV)
Critical aggregation
concentration (CAC) (µg ml−1)
P1. mPEG2000-(LA)50-(tBSC)50 115.8 ± 7.5 −26.9 ± 2.5 9.5
P2. mPEG5000-(LA)50-(tBSC)50 78.5 ± 3.5 −23.5 ± 4.5 8.5
P3. PEG4000-(LA)50-(tBSC)50 92.5 ± 4.5 −10.7 ± 3.5 12.7
P4. 3 armPEG1014-(LA)50-(tBSC)50 138.0 ± 8.0 −29.2 ± 5.5 11.5
P5. 4 armPEG797-(LA)50-(tBSC)50 123.5 ± 1.5 −30.1 ± 5.5 12.1
a Average values from at least 3 sample replicates produced from 3 batches. bMeasurements in milliQ water.
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lation of the extent of BOC deprotection and conversion to free
amine groups on the side chains.
Following the formation of the amine groups on P2, coup-
ling of the widely-used chemotherapeutic, doxorubicin was
carried out using N,N′-disuccinimidyl-carbonate (DSC) as the
coupling-agent, thus linking the drug to the polymer via a
stable urea linkage. The resultant polymer prodrug P2-DOXO
contained ∼10 molecules of doxorubicin based on NMR and
UV analysis, indicating a coupling yield of ∼80% based on the
12–13 free NH2 units available per chain following BOC de-
protection (Fig. 6). The final weight percentage of DOXO in the
polymeric prodrug system varied by less than 10% when
measured by the two spectroscopic techniques (e.g. for 10
units 18% w/w by NMR and 12% by UV-Vis). The polymer
prodrug was subsequently formulated into nanoparticles, with
a size range of 130–145 nm as indicated by DLS and confirmed
by TEM (Fig. 6). The increase in size over the plain polymer
nanoparticles was attributed to the change in chain packing
due to the pendant doxorubicin molecules, while the zeta
potential remained negative confirming an external PEG-
corona (−19.0 ± 0.5 mV). Further indirect evidence of doxo-
rubicin coupling was obtained from experiments in which the
deprotected polymer (P2*) was formulated into nanoparticles
prior to drug conjugation. As can be observed in Fig. S14,† two
populations of nanoparticles were present, indicating dis-
rupted self-assembly of the polymer due to the presence of the
side-chain amines, and in contrast to the defined self-assem-
bly of P2-DOXO. In addition, the zeta-potential of the P2*
nanoparticle suspension was positive (+11 mV), again indica-
tive of free amines and a likely inversion of the blocks of the
polymer exposed in aqueous suspension.
Eﬀects of polymer formulations on breast cancer cells
The intended uses of these materials in biomedical appli-
cations required a preliminary screen of their eﬀects on
measures of cellular viability. Polymer P2 was chosen as the
control model nanoparticle formulation and was incubated
with MCF7 breast cancer cells for up to 48 hours’ exposure. No
change in cellular metabolic activity or plasma membrane
Fig. 4 Co-nanoprecipitation of (A) P2 with HB2 and (B) P5 with HB2. (Left) schematics of co-nanoprecipitation process and (right) DLS traces conﬁ-
rming successful encapsulation of the HB. Dotted lines represent polymers alone, green traces represent the mixed in cuvette control and purple
traces represent the successful coformulation.
Fig. 5 1H NMR spectra to show BOC deprotection on the carbonate
unit in the polymer backbone. Spectra recorded after puriﬁcation of the
polymer from 0, 5, 10 and 30 minutes of reaction time.
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integrity was observed after this time as evaluated by the
PrestoBlue assay and monitoring extracellular release of LDH.
These data indicated that the polymer ‘platform’ of PEG-poly
(lactide)-co-poly(carbonate) was well-tolerated by the model
breast cancer cells. In contrast, while the deprotected polymer,
P2* demonstrated no adverse eﬀects in MCF7 cells after
4 hours of exposure, concentration-dependent toxicity was eli-
cited at exposures of 24 hours and longer (Fig. S15†). Cellular
damage was characterised by plasma membrane disruption, as
evidenced by release of LDH and a decline in metabolic
activity, highlighting the lytic activity of the amphiphilic and
positively charged copolymer formed after BOC-deprotection
(Fig. S14†). We then evaluated the eﬀects of the P2-DOXO
polymer, using the conjugate bearing 10 molecules of doxo-
rubicin per polymer chain. As expected, the polymer prodrug
was highly cytotoxic, with an estimated IC50 of 0.007 ±
0.005 µM based on doxorubicin concentration. Intriguingly,
these data indicated that the polymer pro-drug was signifi-
cantly more toxic than the free drug (IC50 of doxorubicin ∼0.07
± 0.01 µM) under the same assay conditions (Fig. 6).
When considered together, the data in this study show a
number of advantages for the polymers synthesised. Our aim
was to explore facile routes to functionalised materials which
are known to be biodegradable and which could be adaptable
for a variety of therapeutic formats. The key to this concept
was to establish if ring-opening polymerisations of cyclic
esters and carbonates could take place under mild reaction
conditions, in high yields and in short reaction times to gene-
rate the ‘platform’ polymers which might further serve as drug
delivery agents. In essence, our aim was to combine and refine
some existing chemistries rather than develop entirely new
polymerisation or derivatisation methodologies. Thus, for the
formation of PEGylated copolymers, which have been exten-
sively studied as self-assembling NPs for drug delivery, it was
necessary to develop a versatile and controllable synthesis with
as few steps as possible, and minimal purification. We found
that the use of DBU catalysed ROP enabled synthesis to take
place within 30 minutes while retaining all the key functional-
ity. In contrast, triazabicyclodecene (TBD) catalysed polymeris-
ation was unsuitable, because although lactide ring-opening
polymerisations occur rapidly with this catalyst (reaction time
<60 s) there was also a tendency of TBD to cleave BOC-pro-
tected functionalities, leading to a fast self-immolative degra-
dation of the growing polymer chain.19,50 Under the conditions
we developed, DBU catalysed the polymer-forming reactions
eﬃciently without any undesired side reactions. The utility of
DBU was further exemplified by the use of HEMA as an
initiator, resulting in a methacrylate-terminated poly(lactide)-
co-poly(carbonate), and it is important to note that again the
reaction times and conditions were critical in order to avoid
transesterification reactions.51 The retention of the methacry-
late group was demonstrated by a facile thiol–ene click reac-
tion in high yield, but also in the use of the compound as a
macromonomer in hyperbranched polymer synthesis. A
number of papers have shown the advantages of hyper-
branched polycarbonates in drug delivery,52–54 and thus we
Fig. 6 A. Structure of the polymeric prodrug mPEG5000-(LA)50-(tBSC)50-DOXO. B. Stacked
1HNMR spectra of the unmodiﬁed mPEG5000-(LA)50-
(tBSC)50 (bottom) and two modiﬁcations of mPEG5000-(LA)50-(tBSC)50-DOXO (middle and top spectra) at two diﬀerent extents of
functionalisation. C. TEM micrographs of the mPEG5000-(LA)50-(tBSC)50-DOXO NPs prodrug. D. IC50 plots of the mPEG5000-(LA)50-(tBSC)50-DOXO
against free doxorubicin in MCF7 cell line.
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aimed to show that well-defined hyperbranched polymers
could be produced in a single step from the macromonomer
with minimal purification. This was easily achieved by RAFT
polymerisation and three single-chain nanoparticle polymers
were generated by this route, with dimensions of 12–30 nm.
These polymers, and also the amphiphilic copolymers pro-
duced from PEG initiators were then rapidly assembled into
kinetically trapped micellar-like nanoparticles by the ‘nanopre-
cipitation’ technique. Across the range of polymers, nano-
particles with hydrophilic outer ‘shells’ and varying from
12–140 nm in diameter were produced, and thus with pro-
perties appropriate for avoiding renal clearance and RES
uptake, and for prolonging circulation times following sys-
temic injection.
The culminating experiments evaluated some exemplar
polymers for drug conjugation and eﬀects on a model cell
line. An important criterion for drug delivery is the loading of
therapeutic molecules on a carrier, and for the linear PEG-
lactide-carbonate polymer P2 after BOC deprotection and
tagging to the formed amine side-chains, a molar ratio of
10–12 doxorubicin moieties per polymer chain was achieved.
This polymer was found to be 10-fold more potent against
MCF-7 cells in culture than the free drug, while the parent
polymer before BOC deprotection was well-tolerated under all
conditions tested. These results are a good indicator that the
materials described in this paper may form a functionalisable
polymer platform for subsequent in vivo evaluation.
Conclusions
In summation, we have shown data for these potential bio-
medical polymers which suggest a number of advantages com-
pared to existing methodologies for biomaterial synthesis.
Firstly, the use of DBU as catalyst for controlled ring-opening
polymerisation enabled a range of polymers to be formed with
good retention of functionality, and these materials were easily
accessible through reactions under ambient and readily-achiev-
able conditions. Secondly, both PEGylated and methacrylated
hybrid copolymers could be generated with minimal purifi-
cation steps, preserving the key functionalities along the poly-
meric backbone and at the terminal positions, allowing for
further modifications with drug molecules and labels for
desired pharmaceutical and medical applications. Finally, the
polymers could be designed for particular architectures or self-
assembly properties but without requiring multiple reactions
steps, and their association into drug delivery nanoparticles was
easily demonstrated with model drugs and a cancer-relevant
cell line. Future work will explore the detailed in vitro and
in vivo applications of selected polymers from this initial study.
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